National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 9521 [2021-03016]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
Dated: February 9, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03015 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 22, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 96).
Date: February 24, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase II: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 24, 2021.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03016 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
9521
FOR FURTHER INFORMATION CONTACT:
Chris Kornak at 240–627–3705 or
Chris.Kornak@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Replication-Competent Adenovirus
Type 4 SARS–CoV–2 Vaccines and
Their Use
Description of Technology
NIAID has produced recombinant
adenovirus type 4 (Ad4), SARS–CoV–2
spike, vectors for administration to
humans. These recombinant vaccines
permit rapid development of high levels
of neutralizing antibodies to SARS–
CoV–2 in experimental animals. This
vaccine is designed to improve the
durability of the immune response by
inducing mucosal and systemic
immunity. Further, this system should
be incredibly simple and efficient when
producing vaccine at scale. This
technology is available for licensing for
commercial development in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
as well as for further development and
evaluation under a research
collaboration.
Potential Commercial Applications
• Vaccine composition(s)
Competitive Advantages
• Stimulates a durable immune
response;
• Induction of mucosal and systemic
immunity;
• Potential for transmission
interruption;
• Intranasal administration minimizes
the impact of pre-existing immunity;
• Notable improvement for
manufacturing yield and cost, ease of
administration, and distribution as
compared to current candidates.
Inventor: Mark Connors, M.D. (NIAID)
Publications: Matsuda et al. Journal of
Clinical Investigation, 2021. (https://
doi.org/10.1172/JCI140794). Matsuda et
al., Science Immunology 2019 (https://
doi.org/10.1126/sciimmunol.aau2710).
Intellectual Property: HHS Reference
E–055–2021; Application No. 63/
138,221.
Licensing Contact: To license this
technology, please contact Chris Kornak
at chris.kornak@nih.gov.
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Page 9521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03016]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
I: Pediatric Formulations of Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 22, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D., Scientific Review
Officer, Scientific Review Program, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, 5601 Fishers
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
I: Pediatric Formulations of Select Second Line Drugs for Treating
Tuberculosis (Topic 96).
Date: February 24, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D., Scientific Review
Officer, Scientific Review Program, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, 5601 Fishers
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2021-1 Phase
II: Pediatric Formulations of Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 24, 2021.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D., Scientific Review
Officer, Scientific Review Program, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, 5601 Fishers
Lane, Room 3F58, Rockville, MD 20892, 240-669-5199,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-03016 Filed 2-12-21; 8:45 am]
BILLING CODE 4140-01-P
